• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » T-cell immunotherapy market may be worth $30B by 2030

T-cell immunotherapy market may be worth $30B by 2030

October 23, 2015
CenterWatch Staff

After the early success of Immune Checkpoint Inhibitors, T-cell immunotherapy has emerged as another innovative and potent arm of the immuno-oncology market. Characterized by features such as target specificity, adaptability and memory, T-cells have been effectively used as tools to mediate an immune response. According to a recent report by Roots Analysis, there are close to 180 therapies across various phases of development.

Apurva Bhardwaj, a principal analyst, said, “The likely growth is supported by a robust and opportunistic pipeline targeting various indications. The T-cell therapy market is expected to make a huge leap over the coming decade and be worth $30 billion by 2030. Innovative research, lucrative rounds of VC funding, discovery of several novel targets and encouraging clinical trial results have emerged as the key drivers of this market.

“Academicians across the globe have significantly contributed by convening the initial research; this has served as the framework for several startups to drive the research forward. Kite Pharma is the current flag-bearer; Novartis, Juno Therapeutics, CBMG, Celyad, Lion Biotechnologies, Immunocore and Adaptimmune are amongst other well-known players.”

Funding from VC firms and strategic investors has been a key enabler behind that evolution. The report confirms that, over the last six years, close to $3 billion was invested across several startups; the trend is unlikely to subside in the near future. In addition, the market also is seeing a growing interest from several technology providers, especially those with capabilities in genome editing and gene transfer, which have developed innovative platforms for engineering of T-cells.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing